Study of South African Dialysis Patients

• Status: Terminated
• Trial end date: 2014-01-01
• Target enrollment: 0
• Participant gender: All

Summary

An observational study to describe the treatment of anaemia in patients with chronic kidney disease, who are receiving dialysis treatment at selected study centres in South Africa.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Darbepoetin alfa

Criteria

Inclusion Criteria:

• Adult patients undergoing chronic haemodialysis or peritoneal dialysis

• Commenced Aranesp therapy 3-6 months prior to enrolment

• Erythropoiesis stimulating agent (ESA) naive or treated with another ESA prior to commencing Aranesp

• Informed consent obtained

Exclusion Criteria:

• Received Aranesp in an interventional study within 6 months prior to start of observation period

• Receive investigational product during the observation period